Refractive outcome shifts toward myopia after combined surgery

Article

Postoperative refractive outcome shifts toward myopia in patients being treated for rhegmatogenous retinal detachment (RRD) with the combination of phacoemulsification and pars plana vitrectomy, compared with patients who underwent combined surgery for other vitreoretinal pathologies

Postoperative refractive outcome shifts toward myopia in patients being treated for rhegmatogenous retinal detachment (RRD) with the combination of phacoemulsification and pars plana vitrectomy, compared with patients who underwent combined surgery for other vitreoretinal pathologies, according to an article published online in the American Journal of Ophthalmology.

Researchers in South Korea conducted a retrospective observational case-control study of 55 patients. All of the patients had had a combined surgery between January 2007 and December 2012: 25 for RRD (the RRD group), and 30 for other vitreoretinal pathology (the control group). They found that the RRD group had a mean shift toward myopia of 0.35 D compared with the control group.

The mean difference between the predicted refractive outcome and the actual postoperative outcome was –0.43 D ± 0.67 (P = 0.046) in the RRD group and –0.08 D ± 0.53 (P = 0.767) in the control group. The mean preoperative intraocular pressure (IOP) was 11.44 mmHg ± 3.15 in the affected eye in the RRD group, and 13.16 mmHg ± 2.73 in the fellow eye (P = 0.045); there was no IOP difference in the affected eye (14.20 mmHg ± 2.95) and fellow eye (14.17 mmHg ± 3.50) in the control group (P = 0.974).

Postoperatively, there was no significant IOP difference in the affected and fellow eyes of both groups. In the RRD group, the refractive difference for all eyes correlated to IOP change (r = 0.659, r2 = 0.435, P

To read an abstract of the study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.